$ALNY Phase 3 meets end point; Gets Analysts’ love

Alnylam Pharmaceuticals (ALNY) successfully completed a Phase 3 clinical trial, APOLLO, assessing RNAi therapeutic Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, and met its primary endpoint.

Gets Analyst love:

Analyst Action Rating Target
Cowen and Company Reiterates Outperform $93.00 -> $117.00
JMP Securities Raises Target Outperform $101.00 -> $128.00
Needham & Company LLC Raises Target $85.00 -> $125.00
Piper Jaffray Companies Reiterates Overweight $110.00 -> $116.00
Stifel Nicolaus Reiterates Hold $56.00 -> $83.00

Check out more such briefs in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Morgan Stanley downgrades $AGN

Citigroup reiterates buy on Allergan PLC. (AGN) with target of $280, while Morgan Stanley downgrades AGN from overweight to equal weight, revising target from $284 to $228. Could impact the share price.

Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.

$GEMP gemcabene Phase 3 planned

Gemphire Therapeutics (GEMP) announces plans to advance gemcabene into Phase 3 clinical development after data showed clinically meaningful reductions in LDL-C and hsCRP across multiple trials. The micro cap stock rose 13% in low volume, in after hours trade.

Check out detailed news in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Insiders sell $ATHX

Insider sales at Athersys, Inc. (ATHX).

Pres, COO -$35,726
Exec Vice Pres, CSO -$32,508

Check out all pharma insider sales in our SeekingAlpha Marketplace Daily Pharma Scoop.

$MRTX target doubled by Citigroup

Citigroup reiterates buy on Mirati Therapeutics (MRTX) doubling the price target to $16. CIBC and Cann initiate coverage with outperform rating and target of $18. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.

Buy reiterated on $EPZM

Cann and Oppenheimer Holdings reiterate buy on Epizyme (EPZM) with price target of $26.

Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.

$IPSEY Xarmelo approved in EU

Ipsen’s (IPSEY) Xarmelo approved in EU for carcinoid syndrome diarrhea

Read the detail in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$GERN is a true binary event for next year

Our daily analysis of a stock with a major event/upside: Geron’s potential with Imetelstat and its agonizingly slow progress towards the market

Geron (GERN) imetelstat can potentially bring about a paradigm shift in non-solid cancer therapeutics. Imet inhibits telomerase, an enzyme that enables malignant cells to replicate with its DNA intact by protecting the ends of chromosomes. Most types of tumors use the telomerase pathway to replicate, and therefore, this approach has the potential to bring about great therapeutic benefit.

Read the full analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.

$AMGN and $AGN catalyst rundown

FDA approves Amgen and Allergan's MVASI™ (bevacizumab-awwb) for the treatment of five types of cancer. Approval based on totality of evidence from global development program showing MVASI™ is highly similar to Avastin® (bevacizumab). First ever biosimilar to fight cancer approved by FDA.

Full catalyst rundown available in our daily pharma scoop at SeekingAlpha Marketplace page.

$SUPN good interim data

Supernus Pharmaceuticals (SUPN) came out with good interim data from a phase 3 study of SPN-810 for the treatment of impulsive aggression (IA) in children 6 - 12 years old. More news in our daily pharma scoop in our SeekingAlpha Marketplace page.